Opinion|Videos|June 6, 2024
Tailored Treatments for Non-Segmental Vitiligo in a 38-Year-Old Male Patient
Author(s)Rocco Serrao, MD, FAAD
Rocco Serrao, MD, FAAD, discusses a case of a 38-year-old male with progressive vitiligo, exploring potential triggers and exacerbating factors, as well as lifestyle changes and treatment options to manage symptoms and improve quality of life.
Advertisement
Episodes in this series
- What is your impression of this case?
- What challenges does this case present with, if any?
- Can you discuss any potential triggers or exacerbating factors that may have contributed to the onset and progression of vitiligo in this patient?
- Please comment on any lifestyle modifications or environmental changes that may help manage the symptoms and progression of vitiligo in this patient.
- What differential diagnoses would you consider for this patient and what steps would you complete to confirm this diagnosis?
- What are the key clinical features and diagnostic criteria used to diagnose vitiligo, and how do they differ from other hypopigmentary disorders?
Advertisement
Related to this article
A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.
Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.
A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.
Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.
Phase 2 AMETHYST findings show continued improvements in skin redness and clinician- and patient-reported outcomes with litifilimab.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermatology Times Monthly FDA and Pipeline Review: October 2026
2
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
3
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
4
Updated HS Guidelines Emphasize Biologics and Early Intervention
5